Copeptin and the prognosis of patients with coronary artery disease: a meta-analysis

被引:0
作者
Zhewei Shi
Caizhen Qian
机构
[1] Zhuji Affiliated Hospital of Wenzhou Medical University,Department of Cardiology
来源
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷
关键词
Copeptin; Coronary artery disease; Major adverse cardiovascular events; Meta-analysis; Mortality;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2129 / 2141
页数:12
相关论文
共 244 条
[21]  
Carson-Chahhoud K(2010)Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial Diabetes Care 33 79-565
[22]  
Adams C(2011)C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study Clin Sci (Lond) 121 558-32
[23]  
Nejadghaderi SA(2012)High-sensitivity troponin T and copeptin in non-ST acute coronary syndromes: implications for prognosis and role of hsTnT and copeptin in non-STEACS ScientificWorldJournal 2012 27-763
[24]  
Tsao CW(2012)Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction Heart 98 755-1653
[25]  
Aday AW(2012)Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease Int J Cardiol 162 1644-291
[26]  
Almarzooq ZI(2013)Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes Clin Res Cardiol 102 286-332
[27]  
Alonso A(2014)Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36) J Am Coll Cardiol 63 327-544
[28]  
Beaton AZ(2014)The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study Emerg Med J 31 538-341
[29]  
Bittencourt MS(2016)Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction Int J Cardiol 221 337-27
[30]  
Freitas IA(2018)Serum copeptin levels predict clinical outcomes after successful percutaneous coronary intervention in patients with acute myocardial infarction Ann Lab Med 38 22-421